Baggio, L. L. & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131–2157 (2007).
Article CAS PubMed Google Scholar
Campbell, J. E. & Drucker, D. J. Pharmacology physiology and mechanisms of incretin hormone action. Cell Metab. 17, 819–837 (2013).
Article CAS PubMed Google Scholar
McLean, B. A. et al. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr. Rev. 42, 101–132 (2021).
Drucker, D. J. & Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696–1705 (2006).
Article CAS PubMed Google Scholar
Mulvihill, E. E. & Drucker, D. J. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 35, 992–1019 (2014).
Article CAS PubMed Google Scholar
Hammoud, R. & Drucker, D. J. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat. Rev. Endocrinol. 19, 201–216 (2023).
Article CAS PubMed Google Scholar
Shah, A. D. et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 3, 105–113 (2015).
Article PubMed PubMed Central Google Scholar
Haffner, S. M., Lehto, S., Ronnemaa, T., Pyorala, K. & Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229–234 (1998).
Article CAS PubMed Google Scholar
Drucker, D. J. & Goldfine, A. B. Cardiovascular safety and diabetes drug development. Lancet 377, 977–979 (2011).
Muller, T. D. et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 30, 72–130 (2019).
Article CAS PubMed PubMed Central Google Scholar
Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).
Article CAS PubMed PubMed Central Google Scholar
Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).
Article CAS PubMed Google Scholar
Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392, 1519–1529 (2018).
Article CAS PubMed Google Scholar
Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121–130 (2019).
Article CAS PubMed Google Scholar
Gerstein, H. C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N. Engl. J. Med. 385, 896–907 (2021).
Article CAS PubMed Google Scholar
Braunwald, E. Gliflozins in the management of cardiovascular disease. N. Engl. J. Med. 386, 2024–2034 (2022).
Article CAS PubMed Google Scholar
Pfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247–2257 (2015).
Article CAS PubMed Google Scholar
Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228–1239 (2017).
Article CAS PubMed PubMed Central Google Scholar
Ruff, C. T. et al. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat. Med. 28, 89–95 (2022).
Article CAS PubMed Google Scholar
Viljoen, A. & Bain, S. C. Glucagon-like peptide 1 therapy: from discovery to type 2 diabetes and beyond. Endocrinol. Metab. 38, 25–33 (2023).
Trujillo, J. M., Nuffer, W. & Smith, B. A. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther. Adv. Endocrinol. Metab. 12, 2042018821997320 (2021).
Article CAS PubMed PubMed Central Google Scholar
Nathan, D. M. et al. Glycemia reduction in type 2 diabetes — microvascular and cardiovascular outcomes. N. Engl. J. Med. 387, 1075–1088 (2022).
Drucker, D. J. GLP-1 physiology informs the pharmacotherapy of obesity. Mol. Metab. 57, 101351 (2022).
Article CAS PubMed Google Scholar
Davies, M. J. et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. Diabetes Obes. Metab. 20, 734–739 (2018).
Article CAS PubMed Google Scholar
Kosiborod, M. N. et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes. Metab. 25, 468–478 (2023).
Article CAS PubMed Google Scholar
Lingvay, I. et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity 31, 111–122 (2023).
Article CAS PubMed Google Scholar
Sattar, N., Deanfield, J. & Delles, C. Impact of intentional weight loss in cardiometabolic disease: what we know about timing of benefits on differing outcomes. Cardiovasc. Res. https://doi.org/10.1093/cvr/cvac186 (2023).
Drucker, D. J. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 24, 15–30 (2016).
Article CAS PubMed Google Scholar
Ussher, J. R. & Drucker, D. J. Cardiovascular actions of incretin-based therapies. Circ. Res. 114, 1788–1803 (2014).
Article CAS PubMed Google Scholar
Wallner, M. et al. Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. J. Mol. Cell Cardiol. 89, 365–375 (2015).
Article CAS PubMed Google Scholar
Baggio, L. L. et al. GLP-1 receptor expression within the human heart. Endocrinology 159, 1570–1584 (2018).
Article CAS PubMed PubMed Central Google Scholar
Ban, K. et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117, 2340–2350 (2008).
Article CAS PubMed Google Scholar
McLean, B. A., Wong, C. K., Kabir, M. G. & Drucker, D. J. Glucagon-like peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction. Mol. Metab. 66, 101641 (2022).
Article CAS PubMed PubMed Central Google Scholar
Panjwani, N. et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE-/- mice. Endocrinology 154, 127–139 (2013).
Article CAS PubMed Google Scholar
Kim, M. et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 19, 567–575 (2013).
Article CAS PubMed Google Scholar
Richards, P. et al. Identification and characterisation of glucagon-like peptide-1 receptor expressing cells using a new transgenic mouse model. Diabetes 63, 1224–1233 (2014).
Article CAS PubMed Google Scholar
Pyke, C. & Knudsen, L. B. The glucagon-like peptide-1 receptor — or not? Endocrinology 154, 4–8 (2013).
Article CAS PubMed Google Scholar
Moore-Morris, T. et al. Identification of potential pharmacological targets by analysis of the comprehensive G protein-coupled receptor repertoire in the four cardiac chambers. Mol. Pharmacol. 75, 1108–1116 (2009).
留言 (0)